These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30698142)

  • 21. Retinoid Agonists in the Targeting of Heterotopic Ossification.
    Pignolo RJ; Pacifici M
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrodysplasia ossificans progressiva in Brazil: challenges and strategies to create assistance and educational networks.
    Zorzi AR; Delai PR; Rosa HLC; Brito WE; Montalli VAM; Napimoga JC; Napimoga MH; Nociti FH
    Orphanet J Rare Dis; 2022 Sep; 17(1):348. PubMed ID: 36071499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP).
    Brennan TA; Lindborg CM; Bergbauer CR; Wang H; Kaplan FS; Pignolo RJ
    Bone; 2018 Apr; 109():259-266. PubMed ID: 28851540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
    Kaplan FS; Zeitlin L; Dunn SP; Benor S; Hagin D; Al Mukaddam M; Pignolo RJ
    Bone; 2018 Apr; 109():281-284. PubMed ID: 29241828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
    Upadhyay J; Xie L; Huang L; Das N; Stewart RC; Lyon MC; Palmer K; Rajamani S; Graul C; Lobo M; Wellman TJ; Soares EJ; Silva MD; Hesterman J; Wang L; Wen X; Qian X; Nannuru K; Idone V; Murphy AJ; Economides AN; Hatsell SJ
    J Bone Miner Res; 2017 Dec; 32(12):2489-2499. PubMed ID: 28782882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Technetium-99m MDP demonstration of heterotopic ossification in fibrodysplasia ossificans progressiva.
    Fang MA; Reinig JW; Hill SC; Marini J; Zasloff MA
    Clin Nucl Med; 1986 Jan; 11(1):8-9. PubMed ID: 3080267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pseudomalignant heterotopic ossification.
    Kaplan FS; Gannon FH; Hahn GV; Wollner N; Prauner R
    Clin Orthop Relat Res; 1998 Jan; (346):134-40. PubMed ID: 9577421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging assessment of fibrodysplasia ossificans progressiva: Qualitative, quantitative and questionable.
    Al Mukaddam M; Rajapakse CS; Pignolo RJ; Kaplan FS; Smith SE
    Bone; 2018 Apr; 109():147-152. PubMed ID: 28822792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fibrodysplasia ossificans progressiva and osteoimmunology].
    Katagiri T
    Clin Calcium; 2016 May; 26(5):691-8. PubMed ID: 27117614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrodysplasia ossificans progressiva: The patient voice.
    Cali IL; Rossano L
    Bone; 2018 Apr; 109():291-294. PubMed ID: 28549688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva.
    Eekhoff EMW; Botman E; Coen Netelenbos J; de Graaf P; Bravenboer N; Micha D; Pals G; de Vries TJ; Schoenmaker T; Hoebink M; Lammertsma AA; Raijmakers PGHM
    Bone; 2018 Apr; 109():143-146. PubMed ID: 28826841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP).
    Kaplan FS; Al Mukaddam M; Pignolo RJ
    Bone; 2017 Aug; 101():123-128. PubMed ID: 28465250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrodysplasia (myositis) ossificans progressiva (FOP).
    Ramirez-Gonzalez A; Castañeda-de-la-Fuente A; Castro-Cervantes V; Pineda C; Sandoval H; Hidalgo-Bravo A
    Clin Rheumatol; 2022 Jun; 41(6):1929-1930. PubMed ID: 35348929
    [No Abstract]   [Full Text] [Related]  

  • 35. Fibrodysplasia ossificans progressiva (stone man syndrome): a case report.
    Shah ZA; Rausch S; Arif U; El Yafawi B
    J Med Case Rep; 2019 Dec; 13(1):364. PubMed ID: 31785620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype.
    Kan L; Hu M; Gomes WA; Kessler JA
    Am J Pathol; 2004 Oct; 165(4):1107-15. PubMed ID: 15466378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterotopic Ossification: The Keys to the Kingdom.
    Kaplan FS; Pignolo RJ; Shore EM
    Bone; 2018 Apr; 109():1-2. PubMed ID: 29567209
    [No Abstract]   [Full Text] [Related]  

  • 38. An unusual case of adult onset progressive heterotopic ossification suggesting a variant form of fibrodysplasia ossificans progressiva.
    Jayasundara JA; Punchihewa GL; de Alwis DS
    Singapore Med J; 2012 Apr; 53(4):e83-6. PubMed ID: 22511070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis.
    Ahn J; Serrano de la Pena L; Shore EM; Kaplan FS
    J Bone Joint Surg Am; 2003 Apr; 85(4):667-74. PubMed ID: 12672843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.
    Matsuo K; Chavez RD; Barruet E; Hsiao EC
    Curr Osteoporos Rep; 2019 Dec; 17(6):387-394. PubMed ID: 31721068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.